Article
Phenotypic drug susceptibility testing and genotypic characterization of Bedaquiline resistance in drug resistant Mycobacteriumtuberculosis.
Indian journal of medical microbiology - 1 Jan 2026
Victor Annie Sheeba, V Manigandan, Ninan Marilyn Mary, Gupta Richa, Frederick Asha, Ramachandran Ranjani, Rebekah Grace, Michael Joy Sarojini
Abstract excerpt
PURPOSE: The new drugs bedaquiline, delamanid, and pretomanid have been approved for treating drug-resistant tuberculosis. The World Health Organization currently recommends the BPaL(M) regimen, which lasts 6-9 months, for managing drug-resistant tuberculosis. This study aimed to perform phenotypic drug susceptibility testing and identify mutations linked to bedaquiline resistance through whole genome sequencing....
Topics
- Diarylquinolines
- Humans
- Mycobacterium tuberculosis
- Antitubercular Agents
- Microbial Sensitivity Tests
- Genotype
- India
- Tuberculosis, Multidrug-Resistant
- Prospective Studies
- Mutation
